This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
Feature|Videos|July 16, 2025
Enhancing CDMO Capabilities to Meet Evolving Client Needs
Author(s)Benedikt von Braunmühl, Rentschler Biopharma
Rentschler Biopharma is evolving its CDMO capabilities through strategic partnerships, infrastructure investments, and sustainability initiatives to better support clients' complex biologics programs.
Contract development and manufacturing organizations (CDMOs) play an increasingly vital role in the biopharmaceutical industry—evolving from simple capacity providers to strategic, integrated partners. As biopharma pipelines grow more complex and patient needs become more individualized, CDMOs like Rentschler Biopharma are continuously innovating to support clients in bringing life-changing therapies to market quickly, safely, and sustainably.
Watch this video and learn more about:
- How CDMOs are shifting from service providers to strategic partners with deep expertise and integrated support for complex programs.
- Investing in infrastructure to achieve scalability and how targeted expansions help meet client needs from clinical to commercial production.
- Ways in which environmental initiatives create added value for clients and patients in addition to improved sustainability.
Related to this article
FDA approves Sun Pharma’s Ilumya for active psoriatic arthritis, BioMarin licenses a subcutaneous Fabry enzyme replacement therapy from GC Biopharma and Hanmi, and Lonza expands bioconjugation capacity in Visp to meet rising ADC demand.
In an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 440 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
The first-in-class molecule, licensed to Dianthus as DNTH212 outside Greater China, is designed to block type 1 interferon production and BAFF/APRIL-driven B-cell activity with a single drug.
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
The IL-23p19 inhibitor tildrakizumab becomes the third drug in its class approved for psoriatic arthritis, and the only one given exclusively by a healthcare provider.
Trending on BioPharm International
1
Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand
2
Lilly’s Retatrutide Doubles Ozempic’s Weight Loss in First Phase 3 Head-to-Head Trial
3
FDA Approves Sun Pharma’s Ilumya for Active Psoriatic Arthritis
4
Iovance’s Lifileucel Reaches 52% Response Rate in Biomarker-Selected Lung Cancer Subgroup
5